Selected Grants
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventative Treatment of Episodic Migraine in Pe
Clinical TrialPrincipal Investigator · Awarded by Teva Branded Pharmaceutical Products R&D, Inc · 2022 - 2027A Multicenter, Randomized, DoubleBlind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pedia
Clinical TrialPrincipal Investigator · Awarded by Teva Branded Pharmaceutical Products R&D, Inc · 2022 - 2027A Multicenter, Open-Label Study Evaluating the Long-Term Safety, and Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years
Clinical TrialPrincipal Investigator · Awarded by Teva Branded Pharmaceutical Products R&D, Inc · 2022 - 2027New daily persistent headache: Biomarker Study in Children and Adolescents
ResearchPrincipal Investigator · Awarded by International Headache Society · 2023 - 2025A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of Basimglurant Adjunctive to Ongoing Anticonvulsive
Clinical TrialPrincipal Investigator · Awarded by Noema Pharma · 2022 - 2025A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventative Treatment of Episodic Migraine in Pe
Clinical TrialPrincipal Investigator · Awarded by Teva Branded Pharmaceutical Products R&D, Inc · 2022 - 2027A Multicenter, Randomized, DoubleBlind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pedia
Clinical TrialPrincipal Investigator · Awarded by Teva Branded Pharmaceutical Products R&D, Inc · 2022 - 2027A Multicenter, Open-Label Study Evaluating the Long-Term Safety, and Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years
Clinical TrialPrincipal Investigator · Awarded by Teva Branded Pharmaceutical Products R&D, Inc · 2022 - 2027New daily persistent headache: Biomarker Study in Children and Adolescents
ResearchPrincipal Investigator · Awarded by International Headache Society · 2023 - 2025A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of Basimglurant Adjunctive to Ongoing Anticonvulsive
Clinical TrialPrincipal Investigator · Awarded by Noema Pharma · 2022 - 2025Preventing Epilepsy Using Vigabatrin in Infants With Tuberous Sclerosis Complex (PREVeNT Trial)
ResearchPrincipal Investigator · Awarded by University of Alabama at Birmingham · 2018 - 2021External Relationships
- NobelPharma
- Theranica
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.